Press Releases and Statements Read our latest company news and announcements Image Press Releases Filter and Search Filter by year - Any -20242023202220212020 Search 38 press releases Image BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro. Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and Image BUELACH, Switzerland Press Release BIOTRONIK Announces Its Latest Innovation: Oscar Multifunctional Peripheral Catheter BIOTRONIK announces the FDA 510(k) clearance and CE mark of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter. Physicians in the U.S. have already used the novel device in more than 70 cases. As indicated per Instructions for Use, Oscar is intended for percutaneous transluminal interventions in the peripheral vasculature. The device was developed to provide support during access into and to dilate stenoses in femoral, popliteal and infrapopliteal arteries. The Oscar peripheral multifunctional catheter is comprised of three user-adjustable components: The Image BUELACH, Switzerland Press Release New Data Highlight Promising Angiographic and Safety Profile of BIOTRONIK’s Third Generation Resorbable Magnesium Scaffold Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the BIOMAG-I clinical study at the Cardiovascular Research Technologies (CRT) meeting. 1 At six months the angiographic and clinical data showed a low in-scaffold late lumen loss (LLL) rate and a good safety profile with no scaffold thrombosis. A low proportion of mal-apposed struts after implantation was observed, at six months struts were no longer discernable. The intravascular imaging documented a preservation of the scaffold area with a low mean neointimal area. Bioresorbable scaffolds have Image PARIS, France Press Release BIOMAG-I 12-Month Study Data Highlights Continued Excellent Patient Outcomes With New DREAMS 3G Scaffold In the first-in-human study BIOMAG-I, BIOTRONIK’s new-generation DREAMS 3G resorbable magnesium scaffold (RMS) showed significantly lower in-scaffold late lumen loss (LLL) than its predecessor at 12 months as well as excellent safety and efficacy. Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results in the late breaking trial session at the EuroPCR course. 1 At one-year follow-up, BIOMAG-I data confirmed the excellent safety profile of DREAMS 3G RMS with a low target lesion failure rate of 2.6%. Neither cardiac death and myocardial infarction occurred Image BERLIN, Germany Press Release REACT DX Registry Highlights Relevance of Atrial High-Rate Episode Remote Monitoring in ICD Patients A recent study highlights that implantable cardioverter-defibrillator (ICD) patients with new-onset atrial high-rate episodes (AHRE) often show high stroke risk while not being on oral anticoagulation (OAC), underlining the relevance of continuous AHRE burden monitoring. 1 The study also reports that the combination of BIOTRONIK’s unique DX ICD system with Home Monitoring is an effective and convenient way to detect AHRE. 1 REACT DX is a prospective, multi-center registry that enrolled 234 de novo ICD patients from 14 centers in Germany. It assessed the incidence of new-onset AHRE in an ICD Image Statement Statement on the Cybersecurity of BIOTRONIK Solutions Following WIRED Magazine’s Article on Vulnerabilities in Pacemaker Programmer Systems On August 9, WIRED magazine reported that researchers discovered cybersecurity vulnerabilities in the way pacemaker programmers connected to the software delivery network of a specified manufacturer. The researchers claim that “digital code signing”—the cryptographic validation of the legitimacy and integrity of software—is lacking in the manufacturer’s infrastructure, allowing an attacker to potentially take control of device programmers through malicious updates that can subsequently be spread to implanted pacemakers. 1 None of BIOTRONIK’s devices, programmers or networks are affected by Image BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation Image BUELACH, Switzerland Press Release BIOTRONIK Launches Oscar Multifunctional Peripheral Catheter at LINC 2023 BIOTRONIK is pleased to announce the limited release of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter and start of promotional activities at LINC, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany. As indicated per Instructions for Use, the Oscar catheter is intended for dilation of stenotic segments in peripheral vessels. The device is comprised of three fully user-adjustable components (support catheter with integrated Lock Grip, extendable dilator and length-adjustable PTA balloon). It was developed to provide support during access Image BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG Image Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will Image Statement BIOTRONIK Statement on the Cybersecurity Updates Affecting Medtronic Implantable Cardiac Device Programmers On October 11, the US Food and Drug Administration (FDA) issued a Safety Communication regarding cybersecurity updates affecting Medtronic implantable cardiac device programmers, based on an NCCIC Advisory. 1 According to the FDA’s communication, Medtronic is issuing a software update to address a safety risk caused by cybersecurity vulnerabilities associated with the internet connection in two models of programmers used to download software from the manufacturer’s software distribution network (SDN). Successful exploitation of these vulnerabilities would allow an adversary to influence this Image Statement BIOTRONIK Statement on “SweynTooth” Cybersecurity Vulnerabilities The US Food and Drug Administration has issued a Safety Communication regarding a family of cybersecurity vulnerabilities known as SweynTooth, which may introduce risks for certain medical devices that use Bluetooth Low Energy (BLE) wireless communication technology. If exploited, these vulnerabilities can allow unauthorized users to potentially cause a device to stop working, stop it from working correctly and/or bypass security to access certain device functions. The FDA has said it is not aware of any confirmed adverse events related to these vulnerabilities although software to exploit Pagination Page 1 Page 2 Current page 3 Page 4 Previous page ‹ Previous Next page Next › Subscribe to Our News You must have JavaScript enabled to use this form. Your Name Your Email Subject Message *Fields are mandatory. Latest Blog Posts Show all blog articles Image Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary. Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community. Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro. Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and
Image BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro. Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and
Image BUELACH, Switzerland Press Release BIOTRONIK Announces Its Latest Innovation: Oscar Multifunctional Peripheral Catheter BIOTRONIK announces the FDA 510(k) clearance and CE mark of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter. Physicians in the U.S. have already used the novel device in more than 70 cases. As indicated per Instructions for Use, Oscar is intended for percutaneous transluminal interventions in the peripheral vasculature. The device was developed to provide support during access into and to dilate stenoses in femoral, popliteal and infrapopliteal arteries. The Oscar peripheral multifunctional catheter is comprised of three user-adjustable components: The
Image BUELACH, Switzerland Press Release BIOTRONIK Announces Its Latest Innovation: Oscar Multifunctional Peripheral Catheter BIOTRONIK announces the FDA 510(k) clearance and CE mark of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter. Physicians in the U.S. have already used the novel device in more than 70 cases. As indicated per Instructions for Use, Oscar is intended for percutaneous transluminal interventions in the peripheral vasculature. The device was developed to provide support during access into and to dilate stenoses in femoral, popliteal and infrapopliteal arteries. The Oscar peripheral multifunctional catheter is comprised of three user-adjustable components: The
Image BUELACH, Switzerland Press Release New Data Highlight Promising Angiographic and Safety Profile of BIOTRONIK’s Third Generation Resorbable Magnesium Scaffold Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the BIOMAG-I clinical study at the Cardiovascular Research Technologies (CRT) meeting. 1 At six months the angiographic and clinical data showed a low in-scaffold late lumen loss (LLL) rate and a good safety profile with no scaffold thrombosis. A low proportion of mal-apposed struts after implantation was observed, at six months struts were no longer discernable. The intravascular imaging documented a preservation of the scaffold area with a low mean neointimal area. Bioresorbable scaffolds have
Image BUELACH, Switzerland Press Release New Data Highlight Promising Angiographic and Safety Profile of BIOTRONIK’s Third Generation Resorbable Magnesium Scaffold Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the BIOMAG-I clinical study at the Cardiovascular Research Technologies (CRT) meeting. 1 At six months the angiographic and clinical data showed a low in-scaffold late lumen loss (LLL) rate and a good safety profile with no scaffold thrombosis. A low proportion of mal-apposed struts after implantation was observed, at six months struts were no longer discernable. The intravascular imaging documented a preservation of the scaffold area with a low mean neointimal area. Bioresorbable scaffolds have
Image PARIS, France Press Release BIOMAG-I 12-Month Study Data Highlights Continued Excellent Patient Outcomes With New DREAMS 3G Scaffold In the first-in-human study BIOMAG-I, BIOTRONIK’s new-generation DREAMS 3G resorbable magnesium scaffold (RMS) showed significantly lower in-scaffold late lumen loss (LLL) than its predecessor at 12 months as well as excellent safety and efficacy. Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results in the late breaking trial session at the EuroPCR course. 1 At one-year follow-up, BIOMAG-I data confirmed the excellent safety profile of DREAMS 3G RMS with a low target lesion failure rate of 2.6%. Neither cardiac death and myocardial infarction occurred
Image PARIS, France Press Release BIOMAG-I 12-Month Study Data Highlights Continued Excellent Patient Outcomes With New DREAMS 3G Scaffold In the first-in-human study BIOMAG-I, BIOTRONIK’s new-generation DREAMS 3G resorbable magnesium scaffold (RMS) showed significantly lower in-scaffold late lumen loss (LLL) than its predecessor at 12 months as well as excellent safety and efficacy. Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results in the late breaking trial session at the EuroPCR course. 1 At one-year follow-up, BIOMAG-I data confirmed the excellent safety profile of DREAMS 3G RMS with a low target lesion failure rate of 2.6%. Neither cardiac death and myocardial infarction occurred
Image BERLIN, Germany Press Release REACT DX Registry Highlights Relevance of Atrial High-Rate Episode Remote Monitoring in ICD Patients A recent study highlights that implantable cardioverter-defibrillator (ICD) patients with new-onset atrial high-rate episodes (AHRE) often show high stroke risk while not being on oral anticoagulation (OAC), underlining the relevance of continuous AHRE burden monitoring. 1 The study also reports that the combination of BIOTRONIK’s unique DX ICD system with Home Monitoring is an effective and convenient way to detect AHRE. 1 REACT DX is a prospective, multi-center registry that enrolled 234 de novo ICD patients from 14 centers in Germany. It assessed the incidence of new-onset AHRE in an ICD
Image BERLIN, Germany Press Release REACT DX Registry Highlights Relevance of Atrial High-Rate Episode Remote Monitoring in ICD Patients A recent study highlights that implantable cardioverter-defibrillator (ICD) patients with new-onset atrial high-rate episodes (AHRE) often show high stroke risk while not being on oral anticoagulation (OAC), underlining the relevance of continuous AHRE burden monitoring. 1 The study also reports that the combination of BIOTRONIK’s unique DX ICD system with Home Monitoring is an effective and convenient way to detect AHRE. 1 REACT DX is a prospective, multi-center registry that enrolled 234 de novo ICD patients from 14 centers in Germany. It assessed the incidence of new-onset AHRE in an ICD
Image Statement Statement on the Cybersecurity of BIOTRONIK Solutions Following WIRED Magazine’s Article on Vulnerabilities in Pacemaker Programmer Systems On August 9, WIRED magazine reported that researchers discovered cybersecurity vulnerabilities in the way pacemaker programmers connected to the software delivery network of a specified manufacturer. The researchers claim that “digital code signing”—the cryptographic validation of the legitimacy and integrity of software—is lacking in the manufacturer’s infrastructure, allowing an attacker to potentially take control of device programmers through malicious updates that can subsequently be spread to implanted pacemakers. 1 None of BIOTRONIK’s devices, programmers or networks are affected by
Image Statement Statement on the Cybersecurity of BIOTRONIK Solutions Following WIRED Magazine’s Article on Vulnerabilities in Pacemaker Programmer Systems On August 9, WIRED magazine reported that researchers discovered cybersecurity vulnerabilities in the way pacemaker programmers connected to the software delivery network of a specified manufacturer. The researchers claim that “digital code signing”—the cryptographic validation of the legitimacy and integrity of software—is lacking in the manufacturer’s infrastructure, allowing an attacker to potentially take control of device programmers through malicious updates that can subsequently be spread to implanted pacemakers. 1 None of BIOTRONIK’s devices, programmers or networks are affected by
Image BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation
Image BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation
Image BUELACH, Switzerland Press Release BIOTRONIK Launches Oscar Multifunctional Peripheral Catheter at LINC 2023 BIOTRONIK is pleased to announce the limited release of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter and start of promotional activities at LINC, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany. As indicated per Instructions for Use, the Oscar catheter is intended for dilation of stenotic segments in peripheral vessels. The device is comprised of three fully user-adjustable components (support catheter with integrated Lock Grip, extendable dilator and length-adjustable PTA balloon). It was developed to provide support during access
Image BUELACH, Switzerland Press Release BIOTRONIK Launches Oscar Multifunctional Peripheral Catheter at LINC 2023 BIOTRONIK is pleased to announce the limited release of its Oscar ® ( One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter and start of promotional activities at LINC, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany. As indicated per Instructions for Use, the Oscar catheter is intended for dilation of stenotic segments in peripheral vessels. The device is comprised of three fully user-adjustable components (support catheter with integrated Lock Grip, extendable dilator and length-adjustable PTA balloon). It was developed to provide support during access
Image BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG
Image BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG
Image Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will
Image Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will
Image Statement BIOTRONIK Statement on the Cybersecurity Updates Affecting Medtronic Implantable Cardiac Device Programmers On October 11, the US Food and Drug Administration (FDA) issued a Safety Communication regarding cybersecurity updates affecting Medtronic implantable cardiac device programmers, based on an NCCIC Advisory. 1 According to the FDA’s communication, Medtronic is issuing a software update to address a safety risk caused by cybersecurity vulnerabilities associated with the internet connection in two models of programmers used to download software from the manufacturer’s software distribution network (SDN). Successful exploitation of these vulnerabilities would allow an adversary to influence this
Image Statement BIOTRONIK Statement on the Cybersecurity Updates Affecting Medtronic Implantable Cardiac Device Programmers On October 11, the US Food and Drug Administration (FDA) issued a Safety Communication regarding cybersecurity updates affecting Medtronic implantable cardiac device programmers, based on an NCCIC Advisory. 1 According to the FDA’s communication, Medtronic is issuing a software update to address a safety risk caused by cybersecurity vulnerabilities associated with the internet connection in two models of programmers used to download software from the manufacturer’s software distribution network (SDN). Successful exploitation of these vulnerabilities would allow an adversary to influence this
Image Statement BIOTRONIK Statement on “SweynTooth” Cybersecurity Vulnerabilities The US Food and Drug Administration has issued a Safety Communication regarding a family of cybersecurity vulnerabilities known as SweynTooth, which may introduce risks for certain medical devices that use Bluetooth Low Energy (BLE) wireless communication technology. If exploited, these vulnerabilities can allow unauthorized users to potentially cause a device to stop working, stop it from working correctly and/or bypass security to access certain device functions. The FDA has said it is not aware of any confirmed adverse events related to these vulnerabilities although software to exploit
Image Statement BIOTRONIK Statement on “SweynTooth” Cybersecurity Vulnerabilities The US Food and Drug Administration has issued a Safety Communication regarding a family of cybersecurity vulnerabilities known as SweynTooth, which may introduce risks for certain medical devices that use Bluetooth Low Energy (BLE) wireless communication technology. If exploited, these vulnerabilities can allow unauthorized users to potentially cause a device to stop working, stop it from working correctly and/or bypass security to access certain device functions. The FDA has said it is not aware of any confirmed adverse events related to these vulnerabilities although software to exploit
Image Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary.
Image Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary.
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community.
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community.
Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference
Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference